Technology Bundle ID
TAB-3201

Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5

Applications
Linked ID
E-296-2007-0
Lead Inventors
Harlan Caldwell (NIAID)
ICs
A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct conformation of MOMP in vaccines against chlamydia trachomatis, Serovars B, BA, D, E, AND L2.
Commercial Applications
  • A research material that can be used in the development of assays, validation of products or in quality control.
Competitive Advantages
  • Speed up product development with NIH developed material that has already been tested and validated.

Request More Info

Licensing Contact: